#South Korea #Seoul #SOLTOX #CELSET #botulinum

Introduction of SOLTOX in Global Aesthetic Medicine

On October 28, 2026, CELSET INC., a leading South Korean biotechnology firm specializing in aesthetic medicine, officially launched SOLTOX, its innovative type A botulinum toxin. This marks a significant advancement in CELSET’s commitment to enhancing its global reach within the aesthetic medicine sector, introducing a high-quality product designed to meet the evolving demands of international markets.

Key Attributes of SOLTOX

SOLTOX is available in two formulations: 100 units and 200 units, each highlighted by three main technical characteristics. Firstly, it incorporates a 900 kDa toxin complex, defining the molecular size of the botulinum toxin and its associated proteins. Secondly, the product is presented in a lyophilized form requiring reconstitution prior to administration by qualified medical professionals, ensuring ease of use and adherence to local regulations. Thirdly, an advanced purification process is employed, designed to isolate the desired toxin from unwanted components during production.

The process of purification is critical. It involves sophisticated techniques to yield a product that not only satisfies quality standards but also ensures the highest levels of safety for patients. CELSET has established dedicated procedures for quality control throughout the manufacturing cycle, including preparation, filling, lyophilization, and batch evaluation.

Emphasis on Quality and Scientific Foundation

In marketing SOLTOX, CELSET emphasizes the technical excellence of its product. The company aims to communicate clearly how the formulation is distinctive while aligning with scientific principles in aesthetic medicine. While the specific characteristics are underscored, they are not claimed to guarantee superior patient outcomes, instead focusing on transparent quality processes that support the efficacy claims.

This approach aims to enhance recognition and trust in SOLTOX among medical professionals in aesthetic practices globally. As a product rooted in robust quality control and scientific backing, it is positioned to resonate well within the aesthetic medicine community, catering to healthcare providers’ need for reliable and effective solutions.

Expanding CELSET’s Reach in Aesthetic Medicine

The introduction of SOLTOX is not just about launching a new product but also signifies a strategic move by CELSET to expand its footprint in international markets. The biotechnology and aesthetic medicine sectors in South Korea are gaining visibility, and this product launch showcases CELSET's dedication to leveraging established medical channels and regulatory frameworks that vary by region. These initiatives are crucial for building professional relationships and ensuring SOLTOX's successful entry and growth in foreign markets.

Continuing its commitment to scientific communication, CELSET endeavors to provide clear and coherent branding alongside educational resources for healthcare practitioners in different regions. However, the availability of SOLTOX will depend on specific regulatory requirements in each country, underscoring the importance of navigating varying local laws and standards.

About CELSET INC.

Headquartered in Seoul, South Korea, CELSET INC. is dedicated to advancing the field of aesthetic medicine through innovative biotechnological solutions. SOLTOX embodies the company’s commitment to distinctive and professional aesthetics branding, setting a new benchmark in botulinum toxin products. As the company forges ahead, it focuses on quality, safety, and technological integrity, establishing itself as a reliable partner in the global aesthetic medicine landscape.

For more inquiries about SOLTOX or to learn more about CELSET INC., visit celset-aesthetics.com.